Antioxidant Status in Tumor Progression

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 5454

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, CS, Italy
Interests: natural product; cancer; oxidative stress biomarkers; modulatory action of nuclear receptors; adipokines in the development and progression of breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Reactive oxygen species play a dual role in the development of cancer. Low concentrations of ROS are essential for many intracellular metabolic processes, while excessive ROS generation disrupts the mechanisms of cancer suppression. In effect, the early stages of carcinogenesis are characterized by an increase in oxidative stress due to a reduced antioxidant defense system, which leads to an increase in the ROS/antioxidant ratio. This imbalance causes oxidative stress resulting in cancer progression.

This Special Issue aims to collect papers relating to the markers of oxidative stress, the molecular mechanisms responsible for the changes in antioxidant status in tumor initiation and progression, and natural and synthetic products in redox modulation to prevent or develop cancer therapies.

Dr. Francesca Giordano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ROS
  • oxidative stress
  • cancer
  • natural products
  • translation pathways

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1459 KiB  
Article
Changes in Faecal Microbiota Profile and Plasma Biomarkers following the Administration of an Antioxidant Oleuropein-Rich Leaf Extract in a Rat Model Mimicking Colorectal Cancer
by Sofia Chioccioli, Gabriele Rocchetti, Jessica Ruzzolini, Silvia Urciuoli, Francesco Vitali, Gianluca Bartolucci, Marco Pallecchi, Giovanna Caderni, Carlotta De Filippo, Chiara Nediani and Luigi Lucini
Antioxidants 2024, 13(6), 724; https://doi.org/10.3390/antiox13060724 - 14 Jun 2024
Viewed by 1853
Abstract
Oleuropein (OLE), a phenolic compound particularly abundant in the olive leaves, has been reported to have beneficial activities against colorectal cancer (CRC). In vitro studies suggested that these latter could be due to a modulation of the intestinal microbiota. Aiming to evaluate if [...] Read more.
Oleuropein (OLE), a phenolic compound particularly abundant in the olive leaves, has been reported to have beneficial activities against colorectal cancer (CRC). In vitro studies suggested that these latter could be due to a modulation of the intestinal microbiota. Aiming to evaluate if OLE could affect the intestinal microbiota and the plasma metabolome, an antioxidant oleuropein-rich leaf extract (ORLE) was administered for one week to PIRC rats (F344/NTac-Apcam1137), a genetic model mimicking CRC. ORLE treatment significantly modulated the gut microbiota composition. Plasma metabolomic profiles revealed a significant predictive ability for amino acids, medium-chain fatty acids, and aldehydes. Pathway analysis revealed a significant decrease in phosphatidylcholine accumulation (LogFC = −1.67) in PIRC rats. These results suggest a significant effect of ORLE administration on faecal microbiota profiles and plasma metabolomes, thereby offering new omics-based insights into its protective role in CRC progression. Full article
(This article belongs to the Special Issue Antioxidant Status in Tumor Progression)
Show Figures

Figure 1

Review

Jump to: Research

21 pages, 1880 KiB  
Review
Understanding the Transcription Factor NFE2L1/NRF1 from the Perspective of Hallmarks of Cancer
by Haomeng Zhang, Yong Liu, Ke Zhang, Zhixuan Hong, Zongfeng Liu, Zhe Liu, Guichen Li, Yuanyuan Xu, Jingbo Pi, Jingqi Fu and Yuanhong Xu
Antioxidants 2024, 13(7), 758; https://doi.org/10.3390/antiox13070758 - 22 Jun 2024
Cited by 3 | Viewed by 2987
Abstract
Cancer cells subvert multiple properties of normal cells, including escaping strict cell cycle regulation, gaining resistance to cell death, and remodeling the tumor microenvironment. The hallmarks of cancer have recently been updated and summarized. Nuclear factor erythroid 2-related factor 1 (NFE2L1, also named [...] Read more.
Cancer cells subvert multiple properties of normal cells, including escaping strict cell cycle regulation, gaining resistance to cell death, and remodeling the tumor microenvironment. The hallmarks of cancer have recently been updated and summarized. Nuclear factor erythroid 2-related factor 1 (NFE2L1, also named NRF1) belongs to the cap’n’collar (CNC) basic-region leucine zipper (bZIP) family. It acts as a transcription factor and is indispensable for maintaining both cellular homoeostasis and organ integrity during development and growth, as well as adaptive responses to pathophysiological stressors. In addition, NFE2L1 mediates the proteasome bounce-back effect in the clinical proteasome inhibitor therapy of neuroblastoma, multiple myeloma, and triple-negative breast cancer, which quickly induces proteasome inhibitor resistance. Recent studies have shown that NFE2L1 mediates cell proliferation and metabolic reprogramming in various cancer cell lines. We combined the framework provided by “hallmarks of cancer” with recent research on NFE2L1 to summarize the role and mechanism of NFE2L1 in cancer. These ongoing efforts aim to contribute to the development of potential novel cancer therapies that target the NFE2L1 pathway and its activity. Full article
(This article belongs to the Special Issue Antioxidant Status in Tumor Progression)
Show Figures

Figure 1

Back to TopTop